title: Early Fesoterodine Fumarate Administration Prevents Neurogenic Detrusor Overactivity in a Spinal Cord Transected Rat Model.
abstract: BACKGROUND
  In spinal cord injury, onset of detrusor overactivity (DO) is detrimental for quality of life (incontinence) and renal risk. Prevention has only been achieved with complex sophisticated electrical neuromodulation techniques.
  
  
  OBJECTIVE
  To assess the efficacy of early fesoterodine fumarate (FF) administration in preventing bladder overactivity in a spinal cord transected (SCT) rat model.
  
  
  METHODS
  33 Sprague-Dawley rats were allocated to 6 groups-Group 1: 3 normal controls; Group 2: 6 SCT controls; Group 3: 6 SCT rats + FF 0.18 mg/kg/d; Group 4: 6 SCT rats + FF 0.12 mg/kg/d; Group 5: 6 SCT rats + FF 0.18 mg/kg/d + 72-h wash-out period; Group 6: 6 SCT rats + FF 0.12 mg/kg/d + 72-h wash-out period. SCT was performed at T10. FF was continuously administered. Cystometry was undertaken 6 weeks after SCT in awake rats recording intermicturition pressure (IMP), baseline pressure, threshold pressure (Pthres) and maximum pressure (Pmax). Normal controls and SCT controls were initially compared using the Mann-Whitney U tests in order to confirm the SCT effect on cystometric parameters. The comparisons in cystometric and metabolic cage parameters between SCT controls and treated rats were done using post-hoc Dunn's tests for Kruskal-Wallis analysis. Statistical testing was conducted at the two-tailed α-level of 0.05.
  
  
  RESULTS
  Pressure parameters were significantly higher in SCT control group compared to normal controls. Six weeks after SCT, IMP was significantly lower in low dose treated group than in SCT controls. Pmax was significantly lower in 3 treated groups compared to SCT controls. Pthres was significantly lower in full time treated groups than in SCT controls.
  
  
  CONCLUSIONS
  Early administration of FF modulates bladder overactivity in a SCT rat model. Whereas short-term prevention has been demonstrated, the long-term should be further analyzed. Clinical application of these results should confirm this finding through randomized research protocols.
authors.affiliation: Department of Urology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
authors.forename: Xavier
authors.initials: X
authors.lastname: Biardeau
authors.affiliation: Department of Urology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
authors.forename: Mikolaj
authors.initials: M
authors.lastname: Przydacz
authors.affiliation: Department of Urology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
authors.forename: Shachar
authors.initials: S
authors.lastname: Aharony
authors.affiliation: Department of Urology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
authors.forename: George
authors.initials: G
authors.lastname: Loutochin
authors.affiliation: Department of Urology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
authors.forename: Lysanne
authors.initials: L
authors.lastname: Campeau
authors.affiliation: Department of Biostatistics, EA2694, University of Lille, CHRU Lille, France.
authors.forename: Maeva
authors.initials: M
authors.lastname: Kyheng
authors.affiliation: Department of Urology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
authors.forename: Jacques
authors.initials: J
authors.lastname: Corcos
mesh_terms: D000818:Animals; D001559:Benzhydryl Compounds / Q000008:administration & dosage*; D004195:Disease Models, Animal; D005260:Female; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D011312:Pressure; D051381:Rats; D013119:Spinal Cord Injuries / Q000150:complications*; D013997:Time Factors; D016896:Treatment Outcome; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology*
chemical_list: D001559:Benzhydryl Compounds; D018727:Muscarinic Antagonists; C526675:fesoterodine